Abstract
Carbamazepine seems to be as effective as phenytoin in the treatment of grand mat and psychomotor epilepsy. It is the drug of first choice in trigeminal neuralgia.
After single oral doses of carbamazepine, the absorption is fairly complete and the elimination half-life is about 35 hours (range 18 to 65 hours). During multiple dosing, the half-life is decreased to 10–20 hours, probably due to autoinduction of the oxidative metabolism of the drug. Phenytoin and barbiturates also induce the metabolism of carbamazepine. After single doses of carbamazepine, elimination follows dose-dependent first order kinetics.
Carbamazepine is metabolised by oxidation before excretion in the urine. In experimental animals, the metabolite carbamazepine-10, 11 -epoxide has anticonvulsant activity comparable with that of the parent drug. The plasma concentration of the metabolite during long-term treatment of epileptic patients varies between 5 and 81% of that of the parent drug. The plasma protein binding of the metabolite is about 50% compared with about 75% for the parent drug. Less than 50% of a given carbamazepine dose has been identified as metabolites in the urine. The quantitatively most important metabolite is the trans-10, 11-dihydro-10, 11-diol.
The kinetics of carbamazepine have been explored to some extent in pregnant women, newborns and children. Plasma levels of carbamazepine seem to decrease during pregnancy, possibly as a result of increased metabolism. The drug readily crosses the placenta and the levels measured in newborns are comparable with maternal plasma concentrations. In newborns exposed to the drug during fetal life, the plasma half-lives were relatively short (8.2 to 28.1 hours) indicating an induction of carbamazepine metabolism during gestation. The pharmacokinetics of carbamazepine in children aged 0.3 to 15 years are comparable with that in adults.
A single daily dose of carbamazepine is insufficient; 2 doses per day are appropriate in most cases, but some patients may benefit from more frequent dosing to avoid side-effects.
Compared with phenytoin, for example, very few controlled studies have been performed to establish the plasma level range of carbamazepine associated with the best therapeutic outcome. However, the best anticonvulsant effect of carbamazepine seems to be obtained at plasma levels of about 5 to 10μ/ml (20 to 40μmol/L). Side-effects are most frequent at higher levels but may also be seen at lower levels.
References
Alexanderson, B.: Pharmacokinetics of nortriptyline in man after single and multiple oral doses: the predictability of steady state plasma concentrations from single dose plasma level data. European Journal of Clinical Pharmacology 4: 82–91 (1972).
Baker. K.M.; Csetenyi, J.; Frigerio, A.; Morselli, P.L.; Parravicini, F. and Pifferi, G.: 10, 11-Dihydro-10, 11-dihydroxy-5H-dibenz [b,f] azepine-5-carboxamide: A metabolite of carbamazepine isolated from human and rat urine. Journal of Medicinal Chemistry 16: 703–705 (1973a).
Baker. K.M.; Frigerio. A.; Morselli. P.L. and Pifferi, G.: Identification of a rearranged degradation product from carbamazepine-10.11-epoxide. Journal of Pharmaceutical Sciences 62: 475–476 (1973b).
Blom. S.: Trigeminal neuralgia: Its treatment with a new anticonvulsant drug (G-32 883). Lancet 1: 839–840 (1962).
Cereghino, J.J.; Broch, J.T.; van Meter, J.C.; Penry, J.K.; Smith, L.D. and White. B.G.: Carbamazepine for epilepsy — A controlled prospective evaluation. Neurology 24: 401–410 (1974).
Cereghino, J.J.; Brock, J.T.; van Meter, J.C.; Penry, J.K.; Smith, L.D. and White, B.C.: The efficacy of carbamazepine combinations in epilepsy. Clinical Pharmacology and Therapeutics 18: 733–741 (1975).
Cereghino, J.J.; van Meter, J.C.: Brock, J.T.; Penry, J.K.; Smith, L.D. and White, B.G.: Preliminary observations of serum carbamazepine concentration in epileptic patients. Neurology 23: 357–366 (1973).
Chambers, R.E.; Homeida, M.; Hunter, K.R. and Teague, R.H.: Salivary carbamazepine concentrations. Lancet 1: 656–657 (1977).
Christiansen, J. and Dam, M.: Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurologia Scandinavica 49: 543–546 (1973).
Christiansen, J. and Dam. M.: Drug interaction in epileptic patients; in Schneider, Janz. Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-Epileptic Drugs, p.197–200 (Springer-Verlag, Berlin 1975).
Christiansen, J. and Dam, M.: Plasma and salivary levels of carbamazepine and carbamazepine-10, 11 -epoxide during pregnancy; in Gardner-Thorpe, Janz, Meinardi and Pippenger (Eds) Antiepileptic Drug Monitoring, p. 128–137 (Pitman Press, Avon, England 1977).
Csetenyi, J.; Baker, K.M.; Frigerio, A. and Morselli, P.L.: Iminostilbene — a metabolite of carbamazepine isolated from rat urine. Journal of Pharmacy and Pharmacology 25: 340–341 (1973).
Dam, M.: and Christiansen, J.: Interaction of propoxyphene with carbamazepine. Lancet 2: 509 (1977).
Dam, M.; Jensen, A. and Christiansen, J.: Plasma level and effect of carbamazepine in grand mal and psychomotor epilepsy. Acta Neurologica Scandinavica, Suppl. 60: 33–38 (1975).
DiSalle, E.; Pacifici, G.M. and Morselli, P.L.: Studies on the plasma protein binding of carbamazepine. Pharmacological Research Communications 6: 193–202 (1974).
Dravet, C.; Mesdjian, E.; Cenraud, B. and Roger, J.: Interaction between carbamazepine and triacetyloleandomycin. Lancet 1: 810–811 (1977).
Eadie, M.J.: Plasma level monitoring of anticonvulsants. Clinical Pharmacokinetics 1: 52–66 (1976).
Eadie, M.J.; Lander, C.M. and Tyrer, J.H.: Plasma drug level monitoring during pregnancy. Clinical Pharmacokinetics 2: 427–436 (1977).
Eichelbaum, M. and Bertilsson, L.: Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography. Journal of Chromatography 103: 135–140 (1975).
Eichelbaum, M.; Bertilsson, L.; Lund, L.; Palmer, L. and Sjoqvist, F.: Plasma levels of carbamazepine and carbamazepine-10, 11-epoxide during treatment of epilepsy. European Journal of Clinical Pharmacology 9: 417–421 (1976a).
Eichelbaum, M.; Bertilsson, L.; Rane, A. and Sjoqvist, F.: Autoinduction of carbamazepine metabolism in man; in Richens and Woodford (Eds) Anticonvulsant Drugs and Enzyme Induction, p. 147–158 (Associated Scientific Publishers, Amsterdam 1976b).
Eichelbaum, M.; Ekbom, K.; Bertilsson, L.; Ringberger, V.A. and Rane, A.: Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. European Journal of Clinical Pharmacology 8: 337–341 (1975).
Ekbom, K.: Carbamazepine. a new symptomatic treatment for the paraesthesiae associated with Lhermitte’s sign. Zeitschrift fur Neurologie 200: 341–344 (1971).
Ekbom, K.: Carbamazepine in the treatment of tabetic lightning pains. Archives of Neurology 26: 374–378 (1972).
Faigle, J.W.; Brechbuhler, S.; Feldmann, K.F. and Richter, W.J.: The biotransformation of carbamazepine; in Birkmayer (Ed) Epileptic Seizures — Behaviour — Pain, p. 127–140 (Huber, Berne 1976).
Faigle, J.W. and Feldmann, K.F.: Pharmacokinetic data of carbamazepine and its major metabolites in man; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-Epileptic Drugs, p. 159–165 (Springer-Verlag, Berlin 1975).
Faigle, J.W.; Feldmann, K.F. and Baltzer, V.: Anticonvulsant effect of carbamazepine. An attempt to distinguish between the potency of the parent drug and its epoxide metabolite; in Gardner-Thorpe, Janz, Meinardi and Pippenger (Eds) Antiepileptic Drug Monitoring, p. 104–109 (Pitman Press, Avon, England 1977).
Farghali-Hassan, Assael, B.M.; Bossi, L.; Garattini, S.; Gerna, M.; Gomeni, R. and Morselli. P.L.: Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. Archives internationales de Phar-macodynamie et de therapie 220: 125–139 (1976).
Farghali-Hassan, Assael, B.M.; Bossi, L. and Morselli, P.L.: Placental transfer of carbamazepine in the rat. Journal of Pharmacy and Pharmacology 27: 956–957 (1975).
Frigerio, A.; Baker, K.M. and Morselli, P.L.: Gas chromatographic-mass spectrometric studies on carbamazepine; in Costa and Holmstedt (Eds) Advances in Biochemical Psychopharmacology, vol. 7, p. 125–134 (Raven Press, New York 1973).
Frigerio. A.; Cavo-Briones, M. and Belvedere, G.: Formation of stable epoxides in the metabolism of tricyclic drugs. Drug Metabolism Reviews 5: 197–218 (1976).
Frigerio, A.; Fanelli, R.; Biandrate, P.; Passerini, G.; Morselli, P.L. and Garattini, S.: Mass spectrometric characterisation of carbamazepine-10, 11-epoxide, a carbamazepine metabolite isolated from human urine. Journal of Pharmaceutical Sciences 61: 1144–1147 (1972).
Frigerio, A. and Morselli, P.L.: Carbamazepine: Biotransformation; in Penry and Daly (Eds) Advances in Neurology, vol 11, p. 295–308 (Raven Press, New York 1975).
Gagneux. A.R.: The chemistry of carbamazepine; in Birkmayer (Ed) Epileptic Seizures — Behaviour — Pain, p. 120–126 (Huber, Berne 1976).
Gamstorp, I.: Treatment with carbamazepine: Children; in Penry and Daly (Eds) Advances in Neurology, vol 11, p.237–246 (Raven Press, New York 1975).
Gauchel, G.; Gauchel, F.D. and Birkofer, L.: A micromethod for the determination of carbamazepine in blood by high speed liquid chromatography. Zeitung der klinische Chemie und klinische Biochemie 1 1: 459–460 (1973).
Gerardin, A. and Hirtz, J.: The quantitative assay of carbamazepine in biological material and its application to basic pharmacokinetic studies; in. Birkmayer (Ed) Epileptic Seizures — Behaviour — Pain, p. 151–164 (Huber, Berne 1976).
Glatt, H.R.; Oesch, F.; Frigerio, A. and Garattini, S.: Epoxides metabolically produced from some known carcinogens and from some clinically used drugs: I. Differences in mutagenicity. International Journal of Cancer 16: 787–797 (1975).
Goenechea, S. and Hecke-Seibicke, E.: Beitrag zum Stoffwechsel von Carbamazepine. Zeitung der klinische Chemie und klinische Biochemie 10: 112–113 (1972).
Gruska, H.; Beyer, K.-H.; Kubicki, S. and Schneider, H.: Klinik, Toxikologie und Therapie einer schweren Carbamazepine-Vergiftung. Archiv der Toxikologie 27: 193–203 (1971).
Hansen, J.M.; Siersbaek-Nielsen, K. and Skovsted, L.: Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clinical Pharmacology and Therapeutics 12: 539–543 (1971).
Hempel, E. and Klinger, W.: Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications. Drugs 12: 442–448 (1976).
Hooper, W.D.; Dubetz, D.K.; Bochner, F.; Cother, L.M.; Smith, G.A.; Eadie, M.J. and Tyrer, J.H.: Plasma protein binding of carbamazepine. Clinical Pharmacology and Therapeutics 17: 433–440 (1975).
Hooper, W.D.; Dubetz, D.K.; Eadie, M.J. and Tyrer, J.H.: Preliminary observations on the clinical pharmacology of carbamazepine (Tegretol). Proceedings of the Australian Association of Neurologists 11: 189–198 (1974).
Hvidberg, E.F. and Dam, M.: Clinical pharmacokinetics of anticonvulsants. Clinical Pharmacokinetics 1: 161–188 (1976).
Johannessen, S.I.; Barruzzi, A.; Gomeni, R.; Strandjord, R.E. and Morselli, P.L.: Further observations on carbarnazepine and carbamazepine-10, 11-epoxide kinetics in epileptic patients; in Gardner-Thorpe, Janz, Meinardi and Pippenger (Eds) Antiepileptic Drug Monitoring, p. 110–127 (Pitman Press, Avon 1977).
Johannessen, S.I.; Gerna, M.; Bakke, J.; Strandjord, R.E. and Morselli, P.L.: CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10, 11-epoxide in epileptic patients. British Journal of Clinical Pharmacology 3: 575–582 (1976).
Johannessen, S.I. and Strandjord, R.E.: The concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy. Acta Neurologica Scandinavica 48 (Suppl. 51); 445–446 (1972).
Johannessen, S.I. and Strandjord, R.E.: The influence of phenobarbitone and phenytoin on carbamazepine serum levels; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-epileptic Drugs, p.201–205 (Springer-Verlag, Berlin 1975).
Kupferberg, H.J.: GLC determination of carbamazepine in plasma. J. Pharm. Sci. 61: 284–286 (1972).
Kuroiwa, Y. and Shibasaki, H.: Carbamazepine for tonic seizure in multiple sclerosis. Lancet 1: 116 (1967).
Kutt, H.: Carbamazepine: Chemistry and methods of determinations; in Penry and Daly (Eds), Advances in Neurology, vol. 11, p.249–260 (Raven Press, New York 1975).
Kutt, H. and Penry, J.K.: Usefulness of blood levels of antiepileptic drugs. Archives of Neurology 31: 283–288 (1974).
Levy, R.H.; Lockard, J.S.; Green, J.R.; Friel, P. and Martis, L.: Pharmacokinetics of carbarnazepine in monkeys following intravenous and oral administration. Journal of Pharmaceutical Sciences 64: 302–307 (1975a).
Levy, R.H.; Pitlick, W.H.; Troupin, A.S.; Green, J.R. and Neal, J.M.: Pharmacokinetics of carbamazepine in normal man. Clinical Pharmacology and Therapeutics 17: 657–668 (1975b).
McAuliffe, J.J.; Sherwin, A.L.; Leppik, I.E.; Fayle, S.A. and Pippenger, C.E.: Salivary levels of anticonvulsants: A practical approach to drug monitoring. Neurology 27: 409–413 (1977).
Meinardi, H.: Other antiepileptic drugs — carbamazepine; in Woodbury, Penry and Schmidt (Eds) Antiepileptic Drugs, p.487–496 (Raven Press, New York 1972).
Monaco, F; Riccio, A.; Benna, P.; Covacich, A.; Durelli, L.; Fantini, M.; Furlan, P.M.; Gilli, M.; Mutani, R.; Troni, W.; Gerna, M. and Morselli, P.L.: Further observation on carbamazepine plasma levels in epileptic patients — Relationships with therapeutic and side effects. Neurology 26: 936–943 (1976).
Morselli, P.L.: Carbamazepine: Absorption, distribution, and excretion; in Penry and Daly (Eds) Advances in Neurology, vol. 11, p.279–293 (Raven Press, New York 1975).
Morselli, P.L.; Baruzzi, A.; Gerna, M.; Bossi, L. and Porta, M.: Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain. British Journal of CUnical Pharmacology 4: 535–540 (1977).
Morselli, P.L.; Biandrate, P.; Frigerio, A.; Gerna, M. and Tognoni, G.: Gas chromatographic determination of carbamazepine and carbamazepine-10, 11 -epoxide in human body fluids, in Meijer, Meinardi, Gardner-Thorpe and van der Kleijn (Eds) Methods of Analysis of Anti-epileptic Drugs, p.169–175 (Excerpta Medica, Amsterdam 1973).
Morselli, P.L.; Bossi, L. and Gerna, M.: Pharmacokinetic studies with carbamazepine in epileptic patients; in Birkmayer (Ed) Epileptic Seizures — Behaviour — Pain, p.141–150 (Huber, Berne 1976).
Morselli, P.L.; Gerna, M. and Garattini, S.: Carbamazepine plasma and tissue levels in the rat. Biochemical Pharmacology 20: 2043–2047 (1971).
Morselli, P.L.; Gerna, M.; de Maio, D.; Zanda, G.; Viani, F. and Garattini, S.: Pharmacokinetic studies on carbamazepine in volunteers and in epileptic patients, in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-epileptic Drugs, p. 166–179 (Springer-Verlag, Berlin 1975).
Neuvonen, P.J.; Pentilla, O.; Lehtovaara, R. and Aho, K.: Effect of antiepileptic drugs on the elimination of various tetracycline derivatives. European Journal of Clinical Pharmacology 9: 147–154 (1975).
Oesch, F.: Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica 3: 305–340 (1973).
Palmer, L.; Bertilsson, L.; Collste, P. and Rawlins, M.: Quantitative determination of carbamazepine in plasma by mass fragmentography. Clinical Pharmacology and Therapeutics 14: 827–832 (1973).
Parsonage, M.: Treatment with carbamazepine: Adults; in Penry and Daly (Eds) Advances in Neurology, vol.11, p. 221–234 (Raven Press, New York 1975).
Penttila, O.; Neuvonen, P.J.; Aho, K. and Lehtovaara, R.: Interaction between doxycycline and some antiepileptic drugs. British Medical Journal 2: 470–472 (1974).
Pippenger, C.E.; Paris-Kutt, H.; Penry, J.K. and Daly, D.: Proficiency testing in determinations of antiepileptic drugs. Journal of Analytical Toxicology 1: 118–122 (1977).
Pitlick, W.H.; Levy, R.H.; Troupin, A.S. and Green, J.R.: Pharmacokinetic model to describe self induced decreases in steadystate concentrations of carbamazepine. Journal of Pharmaceutical Sciences 65: 462–463 (1976).
Pynnonen, S. and Sillanpaa, M.: Carbamazepine in mother’s milk. Lancet 2: 563 (1975).
Pynnonen, S.; Sillanpaa, M.; Frey, H. and Iisalo, E.: Carbamazepine and its 10, 11-epoxide in children and adults with epilepsy. European Journal of Clinical Pharmacology 11: 129–133 (1977).
Rane, A.; Bertilsson, L. and Palmer, L.: Disposition of placentally transferred carbamazepine (Tegretol ®) in the newborn. European Journal of Clinical Pharmacology 8: 283–284 (1975).
Rane, A.; Hojer, B. and Wilson, J.T.: Kinetics of carbamazepine and its 10, 11-epoxide metabolite in children. Clinical Pharmacology and Therapeutics 19: 276–283 (1976).
Rane, A.; Shand, D.G. and Wilkinson, G.R.: Disposition of carbamazepine and its 10, 11 -epoxide metabolite in the isolated perfused rat liver. Drug Metabolism and Disposition 5: 179–194 (1977).
Raskin, N.H.; Levinson, S.A.; Hoffman, P.M.; Pickett, J.B.E. and Fields, H.L.: Postsympathectomy neuralgia: Amelioration with diphenylhydantoin and carbamazepine. American Journal of Surgery 128: 75–78 (1974).
Rasmussen, P. and Riishede, J.: Facial pain treated with carbamazepine (Tegretol ®). Acta Neurologia Scandinavica 46: 385–408 (1970).
Rawlins, M.D.; Collste, P.; Bertilsson, L. and Palmer, L.: Distribution and elimination kinetics of carbamazepine in man. European Journal of Clinical Pharmacology 8: 91–96 (1975).
Richens, A. and Dunlop, F.: Serum-phenytoin levels in the management of epilepsy. Lancet 2: 247–248 (1975).
Schneider, H.: Carbamazepine: An attempt to correlate serum levels with anti-epileptic and side effects; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-epileptic Drugs, p.151–158 (Springer-Verlag, Berlin 1975a).
Schneider, H.: Carbamazepine: The influence of other antiepileptic drugs on its serum level; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Antiepileptic Drugs, p. 189–195 (Springer-Verlag, Berlin 1975b).
Simonsen, N.; Olsen, P.Z.; Kuhl, V.; Lund, M. and Wendelboe, J.: A comparative controlled study between carbamazepine and diphenylhydantoin in psychomotor epilepsy. Epilepsia 17: 169–176 (1976).
Strandjord, R.E. and Johannessen, S.I.: A preliminary study of serum carbamazepine levels in healthy subjects and in patients with epilepsy; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-epileptic Drugs, p. 181–188 (Springer-Verlag, Berlin 1975).
Troupin, A.S.; Green, J.R. and Halpern, L.M.: Carbamazepine (Tegretol) as an anticonvulsant — A controlled double-blind comparison with diphenylhydantoin (Dilantin). Acta Neurologica Scandinavica, Suppl. 60: 13–26 (1975).
Wagner, J.G.; Northam, J.I.; Alway, C.D. and Carpenter, O.S.: Blood levels of drug at the equilibrium state after multiple dosing. Nature 207: 1301–1302 (1965).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bertilsson, L. Clinical Pharmacokinetics of Carbamazepine. Clin Pharmacokinet 3, 128–143 (1978). https://doi.org/10.2165/00003088-197803020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-197803020-00003